Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Martí Vallès-Prats"'
1
Akademický článek
Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
Autor: Alberto Martínez-Castelao, Aleix Cases, Alberto Torre Carballada, Javier Torralba Iranzo, Josep Bronsoms, Martí Vallès-Prats, Daniel Torán Monserrat, Elisabet Masso Jimenez
Publikováno v: Nefrología (English Edition), Vol 35, Iss 2, Pp 179-188 (2015)
Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This
Externí odkaz: https://doaj.org/article/67b0e77f68554e5bb0963fd1594ebfa8
Zobrazit plný text záznamu
2
Valoración de calcificaciones vasculares en pacientes dializados mediante los índices de Kauppila y Adragao y su asociación con el índice tobillo brazo
Autor: Jennifer Moreno Perdiguero, Jordi Calabia Martínez, Carme Puigvert Vilalta, Carme Muriana Zamudio, Immaculada Casanovas Grados, Martí Vallès Prats
Publikováno v: Enfermería Nefrológica v.18 suppl.1 2015
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Enfermería Nefrológica, Volume: 18 Supplement 1, Pages: 85-85, Published: 2015
Enfermería Nefrológica, Vol 18, Iss suppl 1, Pp 85-85 (2015)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::401121ddeb9fb56d0e5440ae498057ec
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2254-28842015000500066
Zobrazit plný text záznamu
3
Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
Autor: Alberto, Martínez-Castelao, Aleix, Cases, Alberto Torre, Carballada, Javier Torralba, Iranzo, Josep, Bronsoms, Martí, Vallès-Prats, Daniel Torán, Monserrat, Elisabet Masso, Jimenez, José L, Górriz
Publikováno v: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 35(2)
The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13 g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ad856c56c1e051f60238a3244219b40c
https://pubmed.ncbi.nlm.nih.gov/26300512
Zobrazit plný text záznamu
6
The importance of early haemodiafiltration in the treatment of lactic acidosis associated with the administration of metformin
Autor: Anna, Baró-Serra, Bernat, Guasch-Aragay, Nàdia, Martín-Alemany, Josep M, Sirvent, Martí, Vallès-Prats
Publikováno v: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 32(5)
Metformin is a drug widely used in type 2 diabetic patients. Metformin-associated lactic acidosis (MALA) in diabetic patients is rare but can be serious. However, the relationship between metformin and lactic acidosis is under debate. We present seve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d7b4df8835640cf27d03ab96c88bba73
https://pubmed.ncbi.nlm.nih.gov/23013954
Zobrazit plný text záznamu
7
Fibroblast growth factor 23 (FGF 23) and phosphocalcic metabolism in chronic kidney disease
Autor: Pere, Torguet-Escuder, Bernat, Guasch-Aragay, Jordi, Calabia-Martínez, Nàdia, Martín-Alemany, Isabel, García-Méndez, Gerard, Maté-Benito, Esther, Clapés-Sánchez, Mònica, Sabater-Masdeu, José M, Fernández-Real, Martí, Vallès-Prats
Publikováno v: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 32(5)
The ample information available in relation to FGF 23, calcium, phosphorus, PTH, and 25/1,25 vitamin D has allowed us to define consistent values for each variable in each stage of chronic kidney disease (CKD). These values can define early stages, p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6cef45cc11aba706a1a6dbfd9ffcfe3f
https://pubmed.ncbi.nlm.nih.gov/23013951
Zobrazit plný text záznamu
8
Pathologic cervical fracture in a patient with secondary hyperparathyroidism
Autor: Jordi Pérez-Bovet, Diana Faur, Martí Vallès Prats, Secundino Martín Ferrer
Publikováno v: Kidney International. 83:974
An 84-year-old man with end-stage renal disease from focal and segmental glomerulosclerosis was on hemodialysis for 12 years. His secondary hyperparathyroidism had been treated with calcium mimetics, phosphate binders, and vitamin D analogs, with low
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d751008cd75840fd1c701852c46bc94
https://doi.org/10.1038/ki.2012.465
Zobrazit plný text záznamu
10
Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
Autor: Alberto Torre Carballada, Josep Bronsoms, Elisabet Masso Jimenez, Daniel Torán Monserrat, Alberto Martínez-Castelao, Martí Vallès-Prats, Javier Torralba Iranzo, Aleix Cases
Publikováno v: Nefrología (English Edition), Vol 35, Iss 2, Pp 179-188 (2015)
Nefrología, Vol 35, Iss 2, Pp 179-188 (2015)
Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13 g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486b6af3a1bc1c27233d38ae80fbcfe3
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje